{
  "ticker": "NTI",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02966571",
  "id": "02966571",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250707",
  "time": "0932",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250707/pdf/06ljmzpygsqkww.pdf",
  "summary": "**Key Material Information:**  \n- **Clinical Trial Results Published**: Phase I/II trial results for NTI164 (medicinal cannabis extract) in Rett syndrome published in *Journal of Paediatrics and Child Health*.  \n  - **Findings**:  \n    - Well-tolerated with clinical improvements in neurological, behavioural, and functional measures.  \n    - Potential broader therapeutic benefits targeting neuroinflammation and synaptic function.  \n- **Regulatory/Commercial Implications**: Supports NTI164's scientific validation and future regulatory pathway for Rett syndrome and paediatric neurological disorders.  \n\n**No material trading/capital markets actions announced (e.g., no capital raising, timetable, or financial data disclosed).**",
  "usage": {
    "prompt_tokens": 1167,
    "completion_tokens": 143,
    "total_tokens": 1310,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-06T23:53:10.089867"
}